[ad_1]
Dubai: "Gulf"
Following rapid approval by the US Food and Drug Administration (FDA), the UAE has officially approved a new drug for lymphoma treatment and registration, making it the second-largest country in the world to offer hope for patients with rare blood cancer.
The treatment proposed by AstraZeneca, the largest pharmaceutical group in the world, is an important step in the treatment of leukemia, which forms a heterogeneous group of diseases, some of which affect the social and economic quality of life of patients, as well as than on health systems.
"It is very important to us that the UAE agrees to treat lymphoma after the United States," said Dr. Samer Al-Hallaq, president of the Gulf Pharmaceutical Research and Manufacturers Association. The new treatment offers an additional option for lymphoma patients, as well as the success of our company in the field of blood diseases and our commitment to a scientific approach to oncology. We are proud to be part of the UAE fabric for a long time.
"The approval of this treatment is an important development for cancer patients in the United Arab Emirates and in the region," said Dr. Jürgen Christensen, hematology consultant at the city's hospital.
[ad_2]
Source link
